25 Years of Revolutionary Microplate Reader Technology at the LS2
News Dec 16, 2014
BMG LABTECH, the Microplate Reader Company is Gold sponsor of the LS² Annual Meeting 2015 from January 29-30th in Zurich. A visit to booth #33 at the Campus Irchel of the University of Zurich promises a personal introduction to BMG LABTECH’s high performance microplate readers and latest innovations.
Since its establishment in Offenburg, Germany BMG LABTECH has become a world leader in microplate reading due to continuous development of innovative and unique technologies.
25 successful years in the industry attest the quality and reliability of BMG LABTECH’s products and services. BMG LABTECH will showcase the CLARIOstar® with new Atmospheric Control Unit (ACU) and POLARstar® Omega, at the LS2 Annual Meeting 2015 in Zurich, booth #33.
The CLARIOstar® multimode microplate reader offers filter-like performance with advanced LVF Monochromators™ that provides increased sensitivity over conventional monochromators.
The LVF Monochromators™, along with filters and an UV/ Vis spectrometer can be used for a variety of applications in up to eight different detection modes. With its new Atmospheric Control Unit the CLARIOstar® is able to provide the physiological environment for any cell type, enhancing cell-based microplate assays.
The POLARstar® Omega is equipped with an ultra-fast UV/Vis spectrometer and simultaneous dual emission, representing the best combination of performance and flexibility for all life science applications.
The POLARstar® Omega meets the requirements of RT-QuIC seeding assays as it is very robust and the transport system can handle harsh settings, such as long periods of high-speed shaking.
AIDS Vaccine Design: New Data Offers Important InsightNews
New data published in Immunity further illuminate how some human beings generate powerful, HIV-blocking antibodies. The results offer important insight into a potential AIDS vaccine design.READ MORE
Elpis BioMed Closes Funding Round to Commercialise Novel Technology Platform for Generating Human Cell TypesNews
New Cambridge spin-out company commercialises disruptive technology that enables rapid generation of pure and consistent batches of human cell types. Geographically diversified, top-tier investor team includes key industry leaders to support early company development.READ MORE
Quotient Sciences Acquires Pharmaterials, a UK-based Contract Development and Manufacturing OrganizationNews
Quotient Sciences, the drug development services organization, announces it has acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K..READ MORE